Author/Authors :
Nathan R. Rylander، نويسنده , , teven D. Vold، نويسنده ,
Abstract :
Purpoe
To provide patient and health care provider with calculated yearly cot of topical glaucoma medication.
Deign
Propective, experimental, laboratory tudy.
Method
Uing the average wholeale price and common doing pattern, we calculated the theoretical yearly cot of glaucoma medication.
Reult
Calculated yearly cot ranged from $150.81 for generic timolol maleate 0.5% (Falcon Pharmaceutical, Ltd, Fort Worth, Texa, UA) to $697.42 for Coopt (Merck & Co, Wet Point, Pennylvania, UA), and a high a $873.98 for a three-time-daily doe of Alphagan P 0.15% (Allergan, Inc, Irvine, California, UA). Among brand name β-blocker, yearly cot ranged between $203.47 for Timoptic 0.5% (Merck & Co) and $657.24 for Betoptic (Alcon Laboratorie, Fort Worth, Texa, UA). Generic β-blocker conitently were more economical than their brand-name counterpart. Yearly cot of protaglandin analog ranged from $427.69 for Travatan (Alcon) to $577.62 for Lumigan (Allergan). The two carbonic anhydrae inhibitor Azopt (Alcon) and Truopt (Merck & Co), yielded imilar economic profile. Alphagan P 0.15% had yearly calculated cot of $559.08 for twice daily doing per eye. The generic elective α2-agonit brimonidine tartrate 0.2% (Bauch & Lomb Pharmaceutical, Tampa, Florida, UA) cot approximately $352.89 and $529.34 per year for the repective two and three drop daily per eye regimen.
Concluion
Nonelective β-blocker remain the mot inexpenive cla of glaucoma medication. Bottle ize may impact yearly glaucoma medication expenditure. Cot of glaucoma medication may impact deciion making in the medical management of glaucoma.